← Dashboard
Stock
PFE
Pfizer Inc.Health CarePharmaceuticalsLatest close $266 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
6
27 funds tracked
Ever held
16
Current + past
New this quarter
0
Exited this quarter
0
Marquee-fund ownership over time
Nov 13, 2013May 15, 2018May 15, 2024Feb 17, 2026
Now
6
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $26 | $26 | -0% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $26 | $26 | -0% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $26 | $26 | -0% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $26 | $26 | -0% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $26 | $26 | -0% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $26 | $26 | -0% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Renaissance Technologies 2× in & out | Q2 2025 | Q1 2026 | → $27 | +31% |
| Bridgewater Associates 5× in & out | Q2 2021 | Q4 2025 | → $25 | -19% |
| D1 Capital Partners | Q2 2024 | Q4 2024 | → $23 | -7% |
| Coatue Management | Q1 2022 | Q2 2022 | → $41 | +3% |
| Maverick Capital 4× in & out | Q4 2021 | Q1 2022 | → $40 | +1% |
| Berkshire Hathaway | Q4 2020 | Q1 2021 | → $27 | -1% |
| Appaloosa 2× in & out | Q1 2017 | Q3 2017 | → $21 | +4% |
| Elliott Management | Q2 2016 | Q3 2016 | → $22 | +6% |
| Viking Global Investors | Q1 2016 | Q3 2016 | → $22 | +20% |
| JANA Partners | Q1 2016 | Q3 2016 | → $22 | +20% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at PFIZER INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
3
Filings · last 90d
36
Total on file
718
Recent SEC buffer
Most recent
Jun 1, 2026
30d / 90d windows measured from Jun 1, 2026 — the most recent Form 4 on file — not from today.
- Form 40001225208-26-005687Jun 1, 2026
- Form 40001225208-26-005449May 18, 2026
- Form 40001225208-26-004835May 4, 2026
- Form 40001225208-26-004663Apr 27, 2026
- Form 40001225208-26-004662Apr 27, 2026
- Form 40001225208-26-004661Apr 27, 2026
- Form 40001225208-26-004660Apr 27, 2026
- Form 40001225208-26-004659Apr 27, 2026
- Form 40001225208-26-004658Apr 27, 2026
- Form 40001225208-26-004657Apr 27, 2026
- Form 40001225208-26-004654Apr 27, 2026
- Form 40001225208-26-004652Apr 27, 2026
- Form 40001225208-26-004651Apr 27, 2026
- Form 40001225208-26-004650Apr 27, 2026
- Form 40001225208-26-004554Apr 17, 2026
Showing 15 of 718 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · Pfizer Inc.Annual figures sourced directly from Pfizer Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$62.58B
FY2025-2% YoY
Net income
$7.77B
FY2025-3% YoY
EPS (diluted)
$1.36
FY2025-4% YoY
Free cash flow(?)
$9.08B
FY2025-8% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for PFIZER INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 5, 2026
- 8-KMaterial eventMay 5, 2026
- 8-KMaterial eventApr 27, 2026
- DEF 14AProxy statementMar 12, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 3, 2026
- 8-KPFIZER 8-K DECEMBER 16, 2025Dec 16, 2025
- 8-KMaterial eventNov 21, 2025
- 8-KMaterial eventNov 13, 2025
- 10-QQuarterly reportNov 4, 2025
- 8-KMaterial eventNov 4, 2025
- 10-QQuarterly reportAug 5, 2025
- 8-KMaterial eventAug 5, 2025
- 8-KMaterial eventMay 19, 2025
- 10-QQuarterly reportMay 5, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $27 | $25 | -6% |
| Two Sigma Investments | Q4 2025 | open | $24 | $25 | +4% |
| Renaissance Technologies | Q2 2025 | Q1 2026 | $21 | $27 | +31% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $23 | $21 | -10% |
| Citadel Advisors | Q3 2024 | open | $26 | $25 | -1% |
| Two Sigma Investments | Q3 2024 | Q3 2025 | $26 | $24 | -7% |
| D.E. Shaw | Q3 2024 | open | $26 | $25 | -1% |
| AQR Capital Management | Q3 2024 | open | $26 | $25 | -1% |
| Millennium Management | Q3 2024 | open | $26 | $25 | -1% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $26 | $23 | -9% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $25 | $24 | -5% |
| D1 Capital Partners | Q2 2024 | Q4 2024 | $25 | $23 | -7% |
| Coatue Management | Q1 2022 | Q2 2022 | $40 | $41 | +3% |
| Maverick Capital | Q4 2021 | Q1 2022 | $39 | $40 | +1% |
| Bridgewater Associates | Q2 2021 | Q4 2025 | $31 | $25 | -19% |
| Berkshire Hathaway | Q4 2020 | Q1 2021 | $27 | $27 | -1% |
| Maverick Capital | Q2 2020 | Q1 2021 | $27 | $27 | -0% |
| Bridgewater Associates | Q2 2020 | Q3 2020 | $27 | $27 | +2% |
| Maverick Capital | Q4 2018 | Q2 2019 | $29 | $28 | -2% |
| Bridgewater Associates | Q2 2018 | Q1 2019 | $23 | $28 | +20% |
| Appaloosa | Q1 2017 | Q3 2017 | $20 | $21 | +4% |
| Elliott Management | Q2 2016 | Q3 2016 | $20 | $22 | +6% |
| Appaloosa | Q2 2016 | Q3 2016 | $20 | $21 | +6% |
| Viking Global Investors | Q1 2016 | Q3 2016 | $18 | $22 | +20% |
| JANA Partners | Q1 2016 | Q3 2016 | $18 | $22 | +20% |
| Maverick Capital | Q4 2015 | Q1 2018 | $20 | $23 | +15% |
| Bridgewater Associates | Q3 2015 | Q4 2017 | $21 | $23 | +9% |
| Bridgewater Associates | Q4 2013 | Q2 2015 | $18 | $20 | +12% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.